Status:
COMPLETED
Investigation of Memantine in the Treatment of Memory, Concentration or Attention Problems
Lead Sponsor:
Merz Pharmaceuticals GmbH
Conditions:
Memory Disorder
Retention Disorder, Cognitive
Eligibility:
All Genders
50-80 years
Phase:
PHASE2
Brief Summary
In this study, memantine will be tested in a new indication: in the treatment of subjective memory, concentration, or attention problems (subjective cognitive impairment) in the absence of dementia.
Eligibility Criteria
Inclusion
- Subjective worsening of memory, concentration or attention problems for longer than 6 months
- Subject can confirm that a relative or friend has noticed the memory, concentration or attention problems of the subject
- Experience of the memory, concentration or attention problems at least four times per week
Exclusion
- Significant neurological disease or major psychiatric disorder (e.g. diagnosis of psychosis or dementia)
- Significant systemic illness, such as cancer, heart or kidney failure, uncontrolled diabetes
- History of stroke or seizure, or myocardial infarction within the last year (e.g. by inclusion questionnaire, physician interview)
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
299 Patients enrolled
Trial Details
Trial ID
NCT01261741
Start Date
November 1 2010
End Date
September 1 2011
Last Update
November 27 2013
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitätsklinikum der RWTH Aachen
Aachen, Germany, 52074
2
Praxis Dr. Heidenreich
Böblingen, Germany, 71032
3
Universitätsklinikum Carl Gustav Carus
Dresden, Germany, 01307
4
Praxis Dr. Albrecht
Ellwangen, Germany, 73479